Dabigatran etexilate (PRADAXA): new update information

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency continues to regularly evaluate all available data concerning the risk of serious bleeding following administration of Pradaxa. The benefit of this anticoagulant medicine continues to outweigh the risks, but the CHMP considers it necessary to give clearer recommendations for prescribers and patients to better control the risk of bleeding associated with the administration of this medicine.

 

See "Press release EMA"

 

Contact
vig@fagg-afmps.be

Last updated on 08/06/2012